Swiss CDMO expands biologics development capabilities
The Celonic Group, a Swiss-based contract development and manufacturing organisation (CDMO) specialising in quality biologics, has inaugurated its “Next Generation” Biologics Development Center and Pilot Plant in Basel, Switzerland. This expansion aims to support pharmaceutical companies in developing and optimising processes using advanced bioprocessing technologies.
The new laboratory facilities will focus on Process Intensification and Perfusion technologies, which are poised to significantly reduce the cost and risks associated with scaling up biologic medicine production. These advancements are expected to enhance the affordability and accessibility of biologics globally.
Seamless integration with existing facilities
Celonic’s expanded capabilities will complement its GMP manufacturing site in Heidelberg, Germany, offering comprehensive support throughout the product lifecycle, from initial development to market-scale production.
Samanta Cimitan, CEO of the Celonic Group, highlighted the challenges in scaling biologic drug production, stating: “The cost and complexity of scaling a biologic drug from the lab bench to market-scale production poses a significant barrier to innovation.”
She emphasised that the new facilities, equipped with state-of-the-art bioprocessing technologies, will enable increased production of active ingredients, thereby reducing the cost per gram of finished product.
From left to right:
Christof Klöpper, CEO Basel Area Business & Innovation, Samanta Cimitan, CEO Celonic Group, Samuel Hess, Head of Economic Affairs Canton Basel Stadt
